WO1994018193A1 - Novel heterocyclic aminomethyl-4 piperidine derivatives, their preparation and application in therapy - Google Patents
Novel heterocyclic aminomethyl-4 piperidine derivatives, their preparation and application in therapy Download PDFInfo
- Publication number
- WO1994018193A1 WO1994018193A1 PCT/FR1994/000152 FR9400152W WO9418193A1 WO 1994018193 A1 WO1994018193 A1 WO 1994018193A1 FR 9400152 W FR9400152 W FR 9400152W WO 9418193 A1 WO9418193 A1 WO 9418193A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperidine
- benzodioxan
- methyl
- general formula
- methylamino
- Prior art date
Links
- 0 *BN1CCC(C*CC2OC3=CC=CCC3**2)CC1 Chemical compound *BN1CCC(C*CC2OC3=CC=CCC3**2)CC1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- 5-HT- receptors one of the subtypes of serotoninergic receptors, play an important physiological role. Also, as the various chapters of the book “Brain 5-HT Receptors: Behaviourai and Neurochemical Pharmacology” show (Editors C.T. Dourish, S. Ahlenins, P.H. Hutson,
- 5-HT 1A agonists may be useful for the treatment of anxiety, depression, sleep disorders, vascular and cardiovascular disorders, and the regulation of food.
- Agonists 5-HT-. are also known as inhibitors of gastric secretion (JS Gidda, JM Schaus EP.455.510 A2, 1991).
- the present invention carried out at the Pierre Fabre Research Center, relates to new chemical compounds endowed with agonist activity at 5-HT 1 ⁇ receptors, their preparation and their therapeutic application.
- A represents an oxygen atom, a sulfur atom, or a methylene radical; m can take the values of 0 or 1;
- B represents a carbonyl function (CO) or a methylene
- n can take the values of O or 1; R represents a cycloalkyy radical, monocyclic or polycyclic, C O -C- Q .
- the invention also relates to the salts of the compounds of general formula _ with pharmaceutically acceptable mineral or organic acids.
- the acid employed can be, by way of nonlimiting example, p-toiuessesulfonique acid, or fumaric acid.
- the present invention relates to both racemic mixtures and the various enantiomers of the compounds of general formula _1_ as well as their mixtures in all proportions.
- the compounds of general formula _1_ where B represents a carbonyl radical can be prepared according to the reaction scheme:
- - X represents a water-repellent group such as methylsulfonyloxy, benzenesulfonyloxy, or jo-toluenesulfonyloxy.
- reaction between a compound of general formula 2 ⁇ and a compound of general formula 3 ⁇ is carried out either in the absence or in the presence of a solvent such as toluene, xylene, dimethylformamide or acetonitrile, preferably at a temperature between 50 ° C and 200 ° C, and optionally in the presence of an organic base such as a tertiary or mineral amine, such as an alkali carbonate or hydro-carbonate.
- a solvent such as toluene, xylene, dimethylformamide or acetonitrile
- a compound of general formula 4_ obtained according to the methods described above, is carried out by means of a simple or complex hydride of boron or aluminum, for example, 1 * double hydride of lithium and d aluminum, a diborane / ether complex, or the diborane / methyl sulfide complex, or any other equivalent means, in an inert solvent such as ethyl ether or tetrahydrofuran.
- the reduction can be carried out at room temperature or accelerated by heating to the reflux temperature of the solvent.
- a compound of general formula 5_ is thus obtained which corresponds to the general formula j_ when B represents a methylene.
- R cyclohexyl
- X p_-toluenesulfonyloxy
- the compounds of the invention have been subjected to pharmacological tests which have demonstrated their advantage as substances with therapeutic activities.
- rat cerebral cortices are used.
- the brain is dissected and the cortex is homogenized in 20 volumes of Tris-HCl buffer (50 mil, pH 7.4 at 25 ° C) maintained at 4 ° C.
- the homogenate is centrifuged at 39,000 xg for 10 minutes, the centrifugation pellet is suspended in the same volume of buffer and centrifuged again. After resuspending under the same conditions, the homogenate is incubated for 10 minutes at 37 ° C and then centrifuged again.
- the final pellet is suspended in 80 volumes of reaction buffer containing: pargyline (10 -5 M), CaCl 2 (4 mM) and ascorbic acid (0.1%) in Tris-HCl (50 mM, pH 7 , 4 at 25 ° C).
- the final concentration of tissue in the incubation medium is 10 mg / tube.
- the reaction tubes contain 0.1 ml of different concentrations of ⁇ 3 H_7 ⁇ -OH-DPAT (between 0.06 and 8 nM), 0.1 ml of reaction buffer or 5-HT (10 M, to determine non-specific binding) and 0.8 ml of tissue.
- Displacement experiments are carried out as described by Sleight and Peroutka (Naunyn-Schneideberg Arch. Pharmacol., 343, 106-116, 1991). All the dilutions of the products to be studied are made in the reaction buffer.
- the reaction tubes contain 0.1 ml of J_H_ / 8-OH-DPAT (0.2 nM), 0.1 ml of product to be tested 6-7 concentrations (successive dilutions to 1/10) and 0.8 ml tissue. If the alleged affinity of the products is in the nanomo- laire, the lowest concentration tested is 10-11 M, if the product has an assumed low affinity, the highest concentration tested is 10 -4 M.
- reaction tubes are incubated at 23 ° C for 30 minutes and then rapidly filtered under vacuum on hatman GF / B filters, the tubes are rinsed with 2 x 5 ml of Tris-HCl buffer (50 mM, pH 7.4 at 25 ° C).
- the radioactivity collected on the filter is analyzed in liquid scintillation by adding 4 ml of scintillating liquid
- the dissociation constant (K D ) and the maximum number of binding sites (Bmax) for the radio frequency are estimated from the saturation experiments using the non-linear regression program EBDA / LIGAND (Biosoft) (Munson and Rodbard, Anal. Biochem., 107, 220-239, 1980).
- the affinity constants (Ki) of the reference products are estimated from the displacement experiments using the non-linear regression program EBDA / LIGAND. This method admits that the value of the Hiil coefficient is not different from unity.
- the data from the displacement experiments are analyzed respectively with the one site and two site models and the calculated F makes it possible to determine whether the two site model is more representative of the data obtained than the one site model.
- the pKi values are given as an average + SEM of 3 to 5 experiments.
- Table 2 gives, by way of example, pKi 5-HT 1A for certain derivatives of the invention, compared with Buspirone which is used in clinical practice.
- Table 2 Affinity for the 5-HT-A receptor
- the central activity of the compounds of the invention has been evaluated by their capacity to cause 5-HT syndrome, which is characterized by alternating flexion and extension of the front legs (reciprocal fore-paw treading: FPT), the re ⁇ traction of the lower lip (lower-lip retraction: LLR) and by a posture where the ventral surface of the animal is in contact with the floor of the cage with the extended hind legs (flat body posture: FBP).
- the compounds of the invention can therefore be useful for the treatment of anxiety, depression, sleep disorders, for the regulation of food intake, for the regulation of gastric secretion, and for the treatment of vascular disorders.
- cardiovascular and cerebrovascular such as hypertension or migraine.
- Pharmaceutical preparations containing these active ingredients can be shaped for administration by oral, rectal or parenteral route, for example in the form of capsules, tablets, granules, capsules, liquid solutions, syrups or oral suspensions, and contain the appropriate excipients.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94906261A EP0683775A1 (en) | 1993-02-11 | 1994-02-10 | Heterocyclic 4-aminomethylpiperidine derivatives, their preparation and application in therapy |
AU60033/94A AU6003394A (en) | 1993-02-11 | 1994-02-10 | Novel heterocyclic aminomethyl-4 piperidine derivatives, their preparation and application in therapy |
JP6517735A JPH08506334A (en) | 1993-02-11 | 1994-02-10 | Novel heterocyclic aminomethyl-4 piperidine derivatives, their preparation and therapeutic use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9301525A FR2701479B1 (en) | 1993-02-11 | 1993-02-11 | New heterocyclic derivatives of 4-aminomethyl piperidine, their preparation and their therapeutic use. |
FR93/01525 | 1993-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994018193A1 true WO1994018193A1 (en) | 1994-08-18 |
Family
ID=9443949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1994/000152 WO1994018193A1 (en) | 1993-02-11 | 1994-02-10 | Novel heterocyclic aminomethyl-4 piperidine derivatives, their preparation and application in therapy |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0683775A1 (en) |
JP (1) | JPH08506334A (en) |
AU (1) | AU6003394A (en) |
CA (1) | CA2155849A1 (en) |
FR (1) | FR2701479B1 (en) |
NZ (1) | NZ261331A (en) |
WO (1) | WO1994018193A1 (en) |
ZA (1) | ZA94910B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725989A1 (en) * | 1994-10-20 | 1996-04-26 | Pf Medicament | NOVEL SUBSTITUTED 2- (1- (OMEGA-PHENOXYALCOYLPIPERIDIN-4-YL) AMINOMETHYLENE) -2H-BENZOFURAN-3-ONES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO1998029411A1 (en) * | 1996-12-27 | 1998-07-09 | Knoll Aktiengesellschaft | Sulfonamide compounds having 5-ht receptor activity |
WO1999062902A1 (en) * | 1998-06-03 | 1999-12-09 | Knoll Aktiengesellschaft | N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors |
US7045629B2 (en) | 2001-04-26 | 2006-05-16 | Merck Patent Gmbh | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane |
WO2008052078A2 (en) * | 2006-10-24 | 2008-05-02 | Wyeth | Benzoxathiine and benzoxathiole derivatives and uses thereof |
US7728155B2 (en) | 2003-10-24 | 2010-06-01 | Wyeth Llc | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4910302A (en) * | 1988-12-19 | 1990-03-20 | American Home Products Corporation | Psychotropic polycyclic imides |
EP0445026A1 (en) * | 1990-02-27 | 1991-09-04 | Adir Et Compagnie | Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them |
EP0447292A1 (en) * | 1990-03-07 | 1991-09-18 | Synthelabo | 4-Aminomethyl-piperidine derivatives, their preparation and therapeutic application |
EP0452204A1 (en) * | 1990-04-09 | 1991-10-16 | Adir Et Compagnie | 3-Aminochromane derivatives, procedure for their preparation and pharmaceutical compositions containing them |
-
1993
- 1993-02-11 FR FR9301525A patent/FR2701479B1/en not_active Expired - Fee Related
-
1994
- 1994-02-10 AU AU60033/94A patent/AU6003394A/en not_active Abandoned
- 1994-02-10 WO PCT/FR1994/000152 patent/WO1994018193A1/en not_active Application Discontinuation
- 1994-02-10 EP EP94906261A patent/EP0683775A1/en not_active Withdrawn
- 1994-02-10 NZ NZ261331A patent/NZ261331A/en unknown
- 1994-02-10 ZA ZA94910A patent/ZA94910B/en unknown
- 1994-02-10 JP JP6517735A patent/JPH08506334A/en active Pending
- 1994-02-10 CA CA002155849A patent/CA2155849A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4910302A (en) * | 1988-12-19 | 1990-03-20 | American Home Products Corporation | Psychotropic polycyclic imides |
EP0445026A1 (en) * | 1990-02-27 | 1991-09-04 | Adir Et Compagnie | Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them |
EP0447292A1 (en) * | 1990-03-07 | 1991-09-18 | Synthelabo | 4-Aminomethyl-piperidine derivatives, their preparation and therapeutic application |
EP0452204A1 (en) * | 1990-04-09 | 1991-10-16 | Adir Et Compagnie | 3-Aminochromane derivatives, procedure for their preparation and pharmaceutical compositions containing them |
Non-Patent Citations (1)
Title |
---|
R.A. GLENNON: "Central Serotonin Receptors as Targets for Drug Research", JOURNAL OF MEDICINAL CHEMISTRY, vol. 30, no. 1, January 1987 (1987-01-01), WASHINGTON US, pages 1 - 12 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725989A1 (en) * | 1994-10-20 | 1996-04-26 | Pf Medicament | NOVEL SUBSTITUTED 2- (1- (OMEGA-PHENOXYALCOYLPIPERIDIN-4-YL) AMINOMETHYLENE) -2H-BENZOFURAN-3-ONES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO1996012718A1 (en) * | 1994-10-20 | 1996-05-02 | Pierre Fabre Medicament | NOUVELLES 2-[1-(φ-PHENOXYALCOYLPIPERIDIN-4-YL)AMINOMETHYLENE]-2H-BENZOFURAN-3-ONES SUBSTITUEES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
WO1998029411A1 (en) * | 1996-12-27 | 1998-07-09 | Knoll Aktiengesellschaft | Sulfonamide compounds having 5-ht receptor activity |
US6136825A (en) * | 1996-12-27 | 2000-10-24 | Knoll Aktiengesellschaft | Sulfonamide compounds having 5-HT receptor activity |
WO1999062902A1 (en) * | 1998-06-03 | 1999-12-09 | Knoll Aktiengesellschaft | N-benzodioxanylmethyl-1-piperidyl-methylamine compounds having affinity for 5-ht receptors |
US7045629B2 (en) | 2001-04-26 | 2006-05-16 | Merck Patent Gmbh | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane |
US7728155B2 (en) | 2003-10-24 | 2010-06-01 | Wyeth Llc | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
WO2008052078A2 (en) * | 2006-10-24 | 2008-05-02 | Wyeth | Benzoxathiine and benzoxathiole derivatives and uses thereof |
WO2008052078A3 (en) * | 2006-10-24 | 2008-06-19 | Wyeth Corp | Benzoxathiine and benzoxathiole derivatives and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0683775A1 (en) | 1995-11-29 |
FR2701479A1 (en) | 1994-08-19 |
AU6003394A (en) | 1994-08-29 |
JPH08506334A (en) | 1996-07-09 |
FR2701479B1 (en) | 1995-05-12 |
NZ261331A (en) | 1996-05-28 |
ZA94910B (en) | 1994-08-22 |
CA2155849A1 (en) | 1994-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0457686B1 (en) | Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them | |
EP0307303B1 (en) | 1-[(2-Pyrimidinyl)-aminoalkyl] piperidines, their preparation and their use in therapy | |
EP0302788A1 (en) | 2-[Methyl(4-piperidinyl)]-1,2,3,4-tetrahydro-9H-pyrido[3,4-b] indole derivatives, their preparation and therapeutical use | |
EP0677042B1 (en) | Selective ligands of 5ht1d-5ht1b receptors derived from indole-piperazine useful as medicaments | |
FR2681325A1 (en) | DERIVATIVES OF AMINOMETHYL-4 PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC USE. | |
FR2659323A1 (en) | 4- (AMINOMETHYL) PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. | |
EP0306375A1 (en) | 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their use in therapy | |
EP0343050B1 (en) | 6-phenyl-3-piperazinylalkyl 1h,3h-pyrimidinedione-2,4 derivatives, their preparation and their use in therapy | |
EP0351255B1 (en) | Derivatives of 2-[(4-piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy | |
EP0527081A1 (en) | Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use | |
FR2496103A1 (en) | NOVEL DERIVATIVES OF BENZOPYRAN AND BENZOTHIOPYRAN, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES | |
WO1994018193A1 (en) | Novel heterocyclic aminomethyl-4 piperidine derivatives, their preparation and application in therapy | |
EP1966167A1 (en) | Diaryltriazolmethylamine derivatives, preparation and therapeutic use thereof | |
FR2707639A1 (en) | New indole compounds derived from arylamines as selective 5HT1D and 5HT1B receptor ligands. | |
EP0301936B1 (en) | Piperidine derivatives, their preparation and their therapeutical use | |
EP0101380A2 (en) | N-substituted nicotinamide-1-oxide, its salts, process for their preparation and pharmaceutical compositions containing them | |
EP0486385A1 (en) | Imidazole derivatives, process for their fabrication and pharmaceutical compositions containing them | |
WO1994020466A1 (en) | Novel 2-phenoxy ethylamine derivatives, their preparation and their therapeutical use | |
FR2737494A1 (en) | BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | |
EP0302787B1 (en) | 2-Methyl(4-piperidinyl)-benzofuro[2,3-c] pyridines, their preparation and therapeutical use | |
FR2587333A1 (en) | NOVEL BICYCLIC ALLYLIC ETHERS, THEIR PREPARATION AND THEIR USE AS ANTI-FUNGICIDES AND FUNGICIDES | |
EP0351283A1 (en) | 2-[(4-Piperidinyl)methyl]-2,3-dihydro-1H-isoindole and 2,3,4,5-tetrahydro-1H-benzazepine derivatives, their preparation and therapeutical use | |
FR2681320A1 (en) | N- (4,7-DIMETHOXYINDAN-2-YL) -1- (PHENYLCARBONYL) -N-PROPYL-PIPERIDINE-4-METHANAMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. | |
EP0412898A1 (en) | Oxazolo-pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
EP0522914A1 (en) | 2-Piperidinylpyrimidin-4-carboxamide derivatives, their preparation and their application in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994906261 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 261331 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 1995 495554 Country of ref document: US Date of ref document: 19950803 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2155849 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1994906261 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994906261 Country of ref document: EP |